Author:
Sorkness Christine A.,Wildfire Jeremy J.,Calatroni Agustin,Mitchell Herman E.,Busse William W.,O'Connor George T.,Pongracic Jacqueline A.,Ross Kristie,Gill Michelle A.,Kattan Meyer,Morgan Wayne J.,Teach Stephen J.,Gergen Peter J.,Liu Andrew H.,Szefler Stanley J.
Reference18 articles.
1. National Heart, Lung, and Blood Institute. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma Full Report 2007. August 28, 2007. Available from: www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm. Accessed December 1, 2011.
2. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma;Busse;J Allergy Clin Immunol,2001
3. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects;Fahy;Am J Respir Crit Care Med,1997
4. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy;Holgate;Clin Exp Allergy,2005
5. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE;Humbert;Allergy,2005
Cited by
61 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献